389 related articles for article (PubMed ID: 26099675)
1. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
2. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
4. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
6. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
Treglia G; Castaldi P; Villani MF; Perotti G; de Waure C; Filice A; Ambrosini V; Cremonini N; Santimaria M; Versari A; Fanti S; Giordano A; Rufini V
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169
[TBL] [Abstract][Full Text] [Related]
8. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
9. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
10. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
11. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
12. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
[TBL] [Abstract][Full Text] [Related]
13. Clinical indications for Gallium-68 positron emission tomography imaging.
Khan MU; Khan S; El-Refaie S; Win Z; Rubello D; Al-Nahhas A
Eur J Surg Oncol; 2009 Jun; 35(6):561-7. PubMed ID: 19201567
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
15. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
16. (18)F-DOPA PET/CT revealed synchronous neuroendocrine tumors in two sisters with MEN2A syndrome.
Treglia G; Castaldi P; Rufini V
Endocrine; 2013 Apr; 43(2):458-9. PubMed ID: 23229684
[No Abstract] [Full Text] [Related]
17. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.
Treglia G; Castaldi P; Villani MF; Perotti G; Filice A; Ambrosini V; Cremonini N; Versari A; Fanti S; Giordano A; Rufini V
Recent Results Cancer Res; 2013; 194():385-93. PubMed ID: 22918771
[TBL] [Abstract][Full Text] [Related]
18. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
19. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Pepe G; Bombardieri E; Lorenzoni A; Chiti A
PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor PET beyond the neuroendocrine tumors of the gastrointestinal tract - the review of literature.
Zogala D
Klin Onkol; 2021; 34(4):291-299. PubMed ID: 34905930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
